SCHEMBL5306229

SCHEMBL5306229

Cc1cc(C)cc(N(C(N)=O)c2ccc(-c3ccc(C)c4onc(N)c34)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.51
FLT3 P36888 17/20 0.51
KIT P10721 17/20 0.51
FLT1 P17948 8/20 0.42
CSF1R P07333 7/20 0.42
LCK P06239 5/20 0.42
FYN P06241 5/20 0.42
LYN P07948 5/20 0.42
FLT4 P35916 5/20 0.42
BLK P51451 5/20 0.42
SRC P12931 4/20 0.42
ABL1 P00519 3/20 0.42
AURKA O14965 3/20 0.41
ROCK2 O75116 3/20 0.41
RPS6KA5 O75582 3/20 0.41
MAP4K4 O95819 3/20 0.41
NTRK1 P04629 3/20 0.41
RET P07949 3/20 0.41
FGFR1 P11362 3/20 0.41
FER P16591 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5310153 0.85 KDR (0.49) KDRFLT3KITFLT1CSF1R
SCHEMBL13372655 0.83 KDR (0.44) KDRFLT3KITFLT1CSF1R
SCHEMBL5308026 0.83 KDR (0.62) KDRFLT3KITFLT1CSF1R
SCHEMBL5257214 0.82 KDR (0.51) KDRFLT3KITFLT1CSF1R
SCHEMBL5251524 0.79 KDR (0.50) KDRFLT3KITFLT1CSF1R
SCHEMBL425756 0.77 KDR (0.73) KDRFLT3KITFLT1CSF1R
SCHEMBL424102 0.77 FLT3 (0.54) KDRFLT3KITFLT1CSF1R
SCHEMBL425760 0.76 KDR (0.67) KDRFLT3KITFLT1CSF1R
SCHEMBL6800761 0.75 KDR (0.60) KDRFLT3KITFLT1CSF1R
SCHEMBL13372660 0.74 KDR (0.67) KDRFLT3KITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed